Pyxis licenses 2 oncology ADC programs from Pfizer

By The Science Advisory Board staff writers

March 18, 2021 -- Pyxis Oncology has entered into a worldwide license agreement with Pfizer for the development and commercialization of two antibody-drug conjugate (ADC) candidates and a license to Pfizer's ADC technology platform.

Pyxis is using site-specific conjugation technology to develop highly stable ADCs with superior therapeutic indexes. The company has two ADC candidates in development, PYX-201 and PYX-203.

PYX-201 is a first-in-class, noninternalizing ADC that targets a tumor-restricted antigen that is overexpressed in several solid tumor types to selectively kill tumor cells while enhancing a robust anticancer immune response. PYX-203 is an ADC that targets an antigen expressed in certain hematologic malignancies. PYX-203 utilizes a highly potent DNA-damaging agent designed to reduce the potential development of drug resistance and disease relapse.

Pyxis will also gain access to Pfizer's technology platform, including various payload classes, linker technology, and site-specific conjugation techniques for the future development of additional ADCs.

Pfizer will receive an upfront payment of an undisclosed amount and equity in Pyxis and is eligible to receive development and sales-based milestone payments and tiered royalties on potential sales.

Starpharma, Merck collaborate on new ADCs
Starpharma has signed a research agreement with Merck to conduct preclinical research on dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma's...
Sorrento subsidiary to develop ADC cancer therapies
Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for...
Lantern Pharma, Califia Pharma to launch ADC program
Lantern Pharma is launching the development of an antibody-drug conjugate (ADC) program through an evaluation and potential development agreement with...
MilliporeSigma expands antibody-drug conjugate manufacturing
MilliporeSigma is expanding its high-potent active pharmaceutical ingredient and antibody-drug conjugate manufacturing capabilities with a $65 million...
Exelixis enters collaborations for antibody drug conjugates
Exelixis has entered into two separate partnerships with Catalent and NBE Therapeutics for the discovery and development of multiple antibody-drug conjugates...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter